116 related articles for article (PubMed ID: 9395916)
21. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate.
Sheridan T; Herawi M; Epstein JI; Illei PB
Am J Surg Pathol; 2007 Sep; 31(9):1351-5. PubMed ID: 17721190
[TBL] [Abstract][Full Text] [Related]
22. [Prostate cancer after prostatectomy for benign prostatic hyperplasia].
Hua L; Zhang J; Wu H; Sui Y; Zhang W; Qian L; Wang Z
Zhonghua Nan Ke Xue; 2004 Aug; 10(8):612-3. PubMed ID: 15362527
[TBL] [Abstract][Full Text] [Related]
23. [A prostatic duct carcinoma difficult to distinguish from transitional cell carcinoma: a case report].
Ushida H; Koizumi S; Okada Y
Hinyokika Kiyo; 2004 Aug; 50(8):535-8. PubMed ID: 15471072
[TBL] [Abstract][Full Text] [Related]
24. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range.
Haese A; Dworschack RT; Partin AW
J Urol; 2002 Aug; 168(2):504-8. PubMed ID: 12131298
[TBL] [Abstract][Full Text] [Related]
25. Prostate cancer in patients with an abnormal digital rectal examination and serum prostate-specific antigen less than 4.0 ng/mL.
Bozeman CB; Carver BS; Caldito G; Venable DD; Eastham JA
Urology; 2005 Oct; 66(4):803-7. PubMed ID: 16230142
[TBL] [Abstract][Full Text] [Related]
26. Pure prostatic papillary adenocarcinoma with ductal features.
Yamashita S; Inaba Y; Soma F; Katayama Y
Hinyokika Kiyo; 2005 Mar; 51(3):207-9; discussion 210. PubMed ID: 15852679
[TBL] [Abstract][Full Text] [Related]
27. [A case of papillary adenocarcinoma of the prostate which was difficult to diagnose].
Matsuoka Y; Ishizaka K; Machida T; Oka K
Hinyokika Kiyo; 2001 Oct; 47(10):751-4. PubMed ID: 11758361
[TBL] [Abstract][Full Text] [Related]
28. A long follow-up on prostate specific antigen density and prostate biopsy.
Netto Júnior NR; De Lima ML; Lavoura Júnior Nda S; Apuzzo F; De Lucena RG
Arch Esp Urol; 1998 Dec; 51(10):1050-3. PubMed ID: 9951132
[TBL] [Abstract][Full Text] [Related]
29. Basal cell carcinoma of the prostate: report of a case and review of the published reports.
Segawa N; Tsuji M; Nishida T; Takahara K; Azuma H; Katsuoka Y
Int J Urol; 2008 Jun; 15(6):557-9. PubMed ID: 18489650
[TBL] [Abstract][Full Text] [Related]
30. Prostate cancer screening within a prostate specific antigen range of 3 to 3.9 ng./ml.: a comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests.
Mäkinen T; Tammela TL; Hakama M; Stenman UH; Rannikko S; Aro J; Juusela H; Määttänen L; Auvinen A
J Urol; 2001 Oct; 166(4):1339-42. PubMed ID: 11547069
[TBL] [Abstract][Full Text] [Related]
31. Impact of age, benign prostatic hyperplasia, and cancer on prostate-specific antigen level.
Punglia RS; D'Amico AV; Catalona WJ; Roehl KA; Kuntz KM
Cancer; 2006 Apr; 106(7):1507-13. PubMed ID: 16518812
[TBL] [Abstract][Full Text] [Related]
32. [A case of prostate cancer with cyst formation].
Ishida K; Kubota Y; Takada T; Yamada T; Nakano M; Takahashi Y; Ishihara S; Deguchi T
Hinyokika Kiyo; 2003 Apr; 49(4):235-7. PubMed ID: 12784721
[TBL] [Abstract][Full Text] [Related]
33. Role of AgNOR count and its correlation with serum PSA levels in prostatic lesions.
Goel T; Garg S
Urol Int; 2009; 82(3):286-90. PubMed ID: 19440015
[TBL] [Abstract][Full Text] [Related]
34. Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases.
Wang W; Epstein JI
Am J Surg Pathol; 2008 Jan; 32(1):65-71. PubMed ID: 18162772
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of PSA in the detection of carcinoma of the prostate in patients presenting with acute urinary retention.
McNeill SA; Hargreave TB
J R Coll Surg Edinb; 2000 Aug; 45(4):227-30. PubMed ID: 11130021
[TBL] [Abstract][Full Text] [Related]
36. Immunohistochemical expression of prostate specific antigen (PSA) in benign and malignant tumors of the prostate.
Dema A; Tudose N
Rom J Morphol Embryol; 1998; 44(1-4):93-100. PubMed ID: 15678849
[TBL] [Abstract][Full Text] [Related]
37. Extent of prostatic atrophy in needle biopsies and serum PSA levels: is there an association?
Billis A; Meirelles LR; Magna LA; Baracat J; Prando A; Ferreira U
Urology; 2007 May; 69(5):927-30. PubMed ID: 17482936
[TBL] [Abstract][Full Text] [Related]
38. [Gleason histologic grading of prostate carcinoma in relation to serum PSA, PSA in situ and immunohistochemical expression of 34 beta E12 and P504S].
Xiao Q; Yin H; Lu Z; Meng K; Zhou X
Zhonghua Nan Ke Xue; 2004 May; 10(5):362-5. PubMed ID: 15190830
[TBL] [Abstract][Full Text] [Related]
39. [Small cell carcinoma of the prostate: a case report].
Sakai H; Tsuruta T; Wajiki M
Hinyokika Kiyo; 2004 Apr; 50(4):269-71. PubMed ID: 15188622
[TBL] [Abstract][Full Text] [Related]
40. [Summary of our clinical experience with the determination of serum prostate-specific antigen level in the first five years].
Bánfi G; Kiss F; Kádár A; Romics I
Magy Onkol; 2003; 47(2):165-8. PubMed ID: 12975664
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
